Passage Bio (NASDAQ:PASG) and Avalon GloboCare (NASDAQ:ALBT) Head-To-Head Contrast

Passage Bio (NASDAQ:PASG) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Passage Bio and Avalon GloboCare’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$102.06 million	($1.53)	-0.61
Avalon GloboCare	$1.26 million	2.64	-$16.71 million	($1.41)	-0.21

Avalon GloboCare has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 4.3% of Passage Bio shares are held by company insiders. Comparatively, 64.0% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Passage Bio and Avalon GloboCare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-68.53%	-51.64%
Avalon GloboCare	-1,173.55%	N/A	-58.95%

Analyst Ratings

This is a breakdown of current ratings and price targets for Passage Bio and Avalon GloboCare, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	0	0	3	0	3.00
Avalon GloboCare	0	0	0	0	N/A

Passage Bio presently has a consensus target price of $9.00, indicating a potential upside of 867.74%. Given Passage Bio’s higher probable upside, analysts plainly believe Passage Bio is more favorable than Avalon GloboCare.

Volatility & Risk

Passage Bio has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

About Passage Bio

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.